Study provides new insight on how HER2-low tumors may evolve in breast cancer patients

By | May 9, 2021
The finding that breast tumors can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors.